Will new antischistosomal drugs finally emerge?
It has been often observed that the chemotherapeutic armamentarium against an important disease such as schistosomiasis consists of just one drug, praziquantel. Thus, development of drug resistance is an impending danger, with serious implications for the health protection of many millions of people. This rational and legitimate concern might now begin to be relieved by the recent proposal of a new class of compounds that could represent a novel source of drugs against schistosomiasis.
Cioli
Donato
D
Institute of Cell Biology, CNR, 32 Via Ramarini, 00015 Monterotondo, Rome, Italy. dcioli@ibc.cnr.it
Valle
Cristiana
C
Angelucci
Francesco
F
Miele
Adriana E
AE
D000818:Animals; D020650:Combinatorial Chemistry Techniques; D017277:Drug Approval; D015195:Drug Design; D004351:Drug Resistance; D005978:Glutathione; D006801:Humans; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors / Q000378:metabolism; D009247:NADH, NADPH Oxidoreductases / Q000037:antagonists & inhibitors / Q000378:metabolism; D010084:Oxidation-Reduction; D012547:Schistosoma / Q000187:drug effects / Q000378:metabolism; D012552:Schistosomiasis / Q000188:drug therapy; D012556:Schistosomicides / Q000737:chemistry / Q000145:classification / Q000494:pharmacology*; D013879:Thioredoxins
D009097:Multienzyme Complexes; D012556:Schistosomicides; D013879:Thioredoxins; D009247:NADH, NADPH Oxidoreductases; C466433:thioredoxin glutathione reductase; D005978:Glutathione